Drug-induced Liver Injury (DILI) is becoming a significant public health issue because of its potential impact, not only on patients but also on the development of new drugs. DILI events are also the main cause of regulatory action pertaining to drugs, including denial of marketing approval, restrictions with respect to clinical indications and withdrawal from the marketplace (Lee, 2003; Smith and Schmid, 2006) . Acetaminophen (APAP) is a commonly used and effective analgesic and antipyretic agent for relief of mild and moderate pain and is available as an over-the-counter medication. Overdoses of APAP, however, cause severe acute hepatotoxicity both in animals (Lauterburg et al., 1983) and humans (Black, 1984; Davidson and Eastham, 1966; Thomson and Prescott, 1966; Schiødt et al., 1997) . APAP at therapeutic doses is rapidly metabolized in the liver principally through glucuronidation and sulfation, and only a small portion is oxidized by cytochrome P-450 2E1 to generate a highly reactive and cytotoxic intermediate, N-acetyl-p-benzoquinoneimine (NAPQI), which is quickly conjugated by hepatic glutathione to yield a harmless water-soluble product, mercapturic acid (Lee et ABSTRACT -Acetaminophen (APAP) is a commonly used and effective analgesic and antipyretic agent. However, some patients encounter hepatotoxicity after repeated APAP dosing at therapeutic doses. In the present study, we focused on the nutritional state as one of the risk factors of APAP-induced chronic hepatotoxicity in humans and investigated the contribution of undernourishment to susceptibility to APAP-induced chronic hepatotoxicity using an animal model mimicking undernourished patients. Rats were divided into 2 groups: the ad libitum fed (ALF) and the restricted fed (RF) rats and were assigned to 3 groups (n = 8/group) for each feeding condition. The animals were given APAP at 0, 300 and 500 mg/kg for 99 days under each feeding condition. Plasma and urinary glutathione-related metabolites and liver function parameters were measured during the dosing period and hepatic glutathione levels were measured at the end of the dosing period. In the APAP-treated ALF rats hepatic glutathione levels were increased and hepatic function parameters were not changed, but in the APAP-treated RF rats hepatic glutathione levels were decreased at 500 mg/kg and hepatic function parameters were increased at 300 and 500 mg/kg. Moreover the urinary endogenous metabolite profile after long-term treatment with APAP in the ALF and RF rats was similar to that in human non-responders and responders to APAP-induced chronic hepatotoxicity, respectively. In conclusion, the RF rats were more sensitive to APAP-induced chronic hepatotoxicity than the ALF rats and were considered to be a useful model to estimate the contribution of the nutritional state of patients to APAP-induced chronic hepatotoxicity.
INTRODUCTION
. When APAP is dosed at higher dose levels in animals and humans, metabolism of APAP through glucronidation and sulfation is saturated and NAPQI is synthesized in enough amounts to cause acute hepatotoxicity . Rodents are less sensitive to APAP-induced acute hepatotoxicity than humans and this species difference is accounted for by differences in glutathione content, glutathione synthesis activity or conjugation activity of glutathione with drug metabolites in the liver between rodents and humans (Grover and Sims, 1964) . This is evidenced by nonclinical studies using glutathione depletion rodent models that are more sensitive to APAP-induced acute hepatotoxicity than intact rodents (Akai et al., 2007) .
On the market, APAP has been used for long time and is a relatively safe drug when taken as directed at therapeutic doses even in long-term treatment (Amar and Schiff, 2007) . However, it is known that there are responders (susceptibles) and nonresponders (tolerators) in APAP-induced chronic hepatotoxicity even though patients take APAP at therapeutic doses under a prescribed regimen (Amar and Schiff, 2007; O'Connell and Watkins, 2010; Winnike et al., 2010) . Hence, big efforts have been made for a long time to identify the risk factors contributing to APAP-induced chronic hepatotoxicity in clinical field. There have been some reports estimating the risk factors contributing to the APAP-induced chronic hepatotoxicity (Schiødt et al., 1997; Price et al., 1986) . The nutritional state of patients has been identified as one of the risk factors of the APAP-induced hepatotoxicity (Amar and Schiff, 2007 ) and starvation appears to worsen APAP-induced hepatotoxicity after repeated dosing of APAP even at low dose levels (Eriksson et al., 1992) . Hepatic glutathione, which detoxifies an APAP-derived reactive metabolite, NAPQI, is synthesized from several amino acids and undernourishment caused by starvation is considered to lower glutathione stores in the liver through decreased glutathione synthesis due to a low intake of proteins (Buttar et al., 1976) .
In humans, it is known that dietary modulation affects metabolic phenotypes (Stella et al., 2006; Lenz et al., 2004; Zuppi et al., 1998) . Endogenous metabolites provided by pharmaco-metabonomics approach is useful to predict susceptibility to the toxic effects of drugs (Clayton et al., 2006) and to predict how nutritional state of susceptible patients contributes to develop DILI. In clinical area, Winnike et al. (2010) investigated urinary endogenous metabolites and NAPQI-related metabolites in a clinical study with APAP-treated volunteers and revealed that the urinary endogenous metabolite profile was different between responders and nonresponders in APAP-induced hepatotoxicity.
In the present study, we focused on the nutritional state as one of the risk factors for APAP-induced chronic hepatotoxicity in humans and investigated the contribution of undernourishment to susceptibility to APAPinduced chronic hepatotoxicity using an animal model mimicking undernourished patients. Laboratory rodents differ from humans in many ways, including smaller genetic heterogeneity and narrower variation in diet and lifestyle. Further, intact rats more easily adapt to drugs including APAP than humans (O'Brien et al., 2000; Buttar et al., 1976 Buttar et al., , 1977 Strubelt et al., 1979; Poulsen and Thomsen, 1988; Shayiq et al., 1999) . Thus, we employed daytime restricted fed (RF) rats as a modified-nutritional state model for human responders to APAP-induced hepatotoxicity because daytime-RF rats are well known to show some characteristic adaptive changes in energy metabolism, glucose synthesis and fatty acid oxidation associated with a shift of the animal's circadian rhythms (Baez-Ruiz et al., 2005; Leveille and Chakrabarty, 1968; Satoh et al., 2006; Wu et al., 2008) and to show acceleration of hepatic gluconeogenesis under restricted feeding conditions (Kobayashi et al., 2011) . In the present study, plasma and urinary endogenous metabolites were also compared between ad libitum fed (ALF) rats and RF rats before and after repeated dosing of APAP.
MATERIALS AND METHODS

Animals
Seven-week-old male Crl:CD (SD) rats were purchased from Charles River Japan Inc. (Kanagawa, Japan). The animals were housed individually in wire-mesh cages kept in an air-conditioned room with a 12-hr light-dark cycle (lighting from 7:00 a.m. to 7:00 p.m.) at a temperature of 23 ± 1°C, a relative humidity of 55 ± 5% and a ventilation rate of about 15 times per hour. The rats were quarantined for 1 week and were allowed free access to a commercial powder diet (CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan) ad libitum during the quarantine period. Tap water was available for drinking ad libitum. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of the Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc. This study was conducted in accordance with the Japanese Law for the Humane Treatment and Management of Animals (Law No. 105, as revised in 2006 , issued in October 1, 1973 .
Feeding conditions and measurements of food consumption and body weights
Forty-eight animals were used for the study. The animals were divided into 2 groups: twenty-four animals each for the ad libitum fed (ALF) group and the restricted fed (RF) group. The rats were acclimated for 2 weeks to adapt to each feeding condition. The RF rats were allowed free access to the diet for 4 hr per day from 10:00 a.m. to 2:00 p.m. only. After the acclimation, the animals were divided into 3 groups (n = 8/group) for each feeding condition based on food consumption during the acclimation period and body weights on the day of allocation so that the mean food consumption and initial body weights of each group in each feeding condition were equivalent. Food consumption per day (absolute food consumption) and food consumption relative to body weight (relative food consumption) was calculated on days 14, 35, 56, 77 and 98 during the dosing period for all animals. Body weights were measured on days 1 (just before the initiation of dosing), 14, 35, 56, 77 and 99 in each morning (before feeding for the RF groups).
Dosing of APAP
APAP was purchased from Wako Pure Chemical Industry (Osaka, Japan) and was suspended in 0.5% methylcellulose (MC, Shin-etsu Chemical Co., Ltd., Tokyo, Japan) aqueous solution. The high dose level was set at 500 mg/kg which is comparable to the upper limit therapeutic dose (4 g/day) in body surface area equivalent and low dose level was set at 300 mg/kg. The rats both in the ALF and RF groups were given APAP once daily (between 2:00 p.m. and 3:00 p.m.) for 99 days.
Sampling of blood samples
Blood samples were collected between 8:00 a.m. and 10:00 a.m. during the pre-dosing period (just before the initiation of dosing, described in the figures as "Pre") and on days 8, 21, 35, 49, 63, 77 and 98 . Blood samples were collected from the subclavian vein into sodium heparin-treated syringes. An aliquot of each blood sample was mixed with the same volume of 0.8% (w/v) perchloric acid for the measurement of the pyruvic acid (PA) levels. Plasma samples were obtained by centrifugation (9000 rev•min -1 , 4°C, 15 min) and used for the measurement of glucose, PA, lactic acid (LA), creatinine (CRN), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamate dehydrogenase (GLDH) levels. On day 99 additional blood samples were collected for the measurement of the plasma APAP concentrations at 4 hours after dosing APAP when the plasma APAP concentrations were considered to reach their maximum level from the results of preliminary studies and at 19 hr after dosing APAP. The plasma samples were obtained in the same manner as the above-mentioned samples. These plasma samples were stored at -80°C until use.
Sampling of urine samples
Urine samples were collected once during the predosing period (four days before the initiation of dosing, described in the figures as "Pre") and on days 36, 64 and 99 of the dosing period. The animals were placed in metabolism cages (Tokiwa Kagaku Kikai Co., Ltd., Tokyo, Japan) to collect the urine samples for approximately 24 hr. The animals were placed in metabolism cages immediately after dosing. After measurement of the volume, the urine samples were stored at -80°C until use.
Sampling of Liver samples
All the animals were euthanized by exsanguination from the abdominal aorta under ether anesthesia without fasting for the ALF groups and under fasted conditions (fasted for about 20 hr after the last restricted feeding) for the RF groups on the day following the last dosing. The livers were removed, weighed and aliquots of the samples were stored at -80°C until use. The remaining samples were preserved in neutral buffered formalin for histopathological examination. and used as the internal standards for CR, TAU and CRN, respectively. For the urinary endogenous metabolites, the excretion per day was calculated for each metabolite by multiplying the urine volumes and the concentrations.
Assay of hepatic GSH and GSSG levels
A liver sample of approximately 1 g was collected from each animal. All the samples were immediately frozen in liquid nitrogen and stored at -80°C until the following experiments. The frozen liver samples were thawed and 5% 5-sulfosalicylic acid aqueous solution (Wako Pure Chemical, Tokyo, Japan) was added to the samples at a volume of 9 ml per 1 g wet tissue weight. The tissue samples were homogenized using a Tissuelyser System (QIAGEN, Tokyo, Japan). The homogenates were centrifuged at 8,000 g for 10 min at 4°C and the supernatants were obtained for measurement of the hepatic reduced glutathione (GSH) and oxidized glutathione (GSSG) concentrations. Hepatic GSH and GSSG concentrations in the supernatants were measured by an enzyme recycling method using GSH/GSSG quantification kit (Dojindo laboratories, Kumamoto, Japan).
Measurements of plasma hepatic function parameters
Plasma AST, ALT and GLDH activities were measured at 37°C with a TBA-120FR automated analyzer using standard reagents by UV method for AST, ALT (Wako Pure Chemical, Tokyo, Japan) and GLDH (RANDOX Laboratories Ltd., Antrim, UK).
Histopathological examination in the liver
Left lobe of the liver was cut into longitudinal sections. The liver slices were embedded in paraffin. Sectioning and hematoxylin-eosin staining was performed according to routine histological procedures.
Measurements of plasma APAP concentrations
Plasma APAP concentrations were measured by high performance liquid chromatography (HPLC), using a 10A series (Shimadzu, Kyoto, Japan), after deproteination. Plasma APAP concentrations at 4 and 19 hr after dosing on day 99 (C 4hr and C 19hr , respectively) were determined. The area under the concentration-time curve values from 4 to 19 hr after APAP dosing were calculated by trapezoidal method.
Statistical analysis
The mean values and standard deviations in each group were calculated for the food consumption, body weights, plasma glucose, plasma and urinary endogenous metabolites, hepatic function parameters for each day of measurement, and liver weights, hepatic GSH and GSSG concentrations at necropsy and plasma APAP concentrations at 4 and 19 hr after APAP dosing and systemic exposure to APAP ) on day 99. A Student's t test was conducted for comparison of the food consumption, body weights, plasma glucose, plasma and urinary endogenous metabolites, liver function parameters and hepatic GSH and GSSG concentrations between the ALF and RF control groups and for comparison of the plasma APAP concentrations between the ALF and RF group at the same dose level. A Williams' test was conducted for comparison of these data between the control group and APAP-treated groups each for the ALF and RF groups using a statistical software package, Pharmaco Analyst II (Hakuhousya, Tokyo, Japan). The data of all the parameters were analyzed by a Student's t test or Williams' test after logarithmic transformation. The levels of significance were set at 5% and 1% (two-tailed).
RESULTS
Comparison of the control data between the ALF and RF groups
Food consumption per animal per day in the RF control group was lower than that in the ALF control group throughout the experimental period but the relative food consumption in the RF control group was comparable to that in the ALF control group throughout the experimental period. Body weights in the RF control group were lower than those in the ALF control group throughout the experimental period. The plasma glucose levels in the RF control group were lower than those in the ALF control group in the early phase of the experimental period, but were almost comparable to those in the ALF group in the latter half of the experimental period. The plasma PA and LA levels in the RF control group were comparable to those in the ALF control group throughout the experimental period, although some statistically significant changes were noted. The plasma CRN concentrations in the RF control group were lower than those in the ALF control group during the pre-dosing period and were slightly higher than those in the ALF control group on the other sampling point. The urinary excretion of CR and CRN in the RF control group was lower than that in the ALF control group throughout the experimental period, although the change was not statistically significant for some sampling days. The urinary TAU excretion in the RF control group was lower than that in the ALF control group during the pre-dosing period although the difference was not statistically significant and was compara- 14.7 ± 2.8 13.5 ± 0.9 49 14.8 ± 3.9 15.0 ± 2.4 63 17.0 ± 3.1 13.4 ± 1.3 77 16.1 ± 3.0 13.4 ± 1.8 98 14.3 ± 3.5 12.8 ± 3.0
Abbreviation: GLU; glucose, PA; pyruvic acid, LA; lactic acid;, CRN; creatinine, CR; creatine, TAU; taurine, GSH; reduced glutathione, GSSG; oxidized glutathione, AST; aspartate aminotransferase, ALT; alanine aminotransferase, GLDH; glutamate dehydrogenase All the parameters were measured for each rat (the pre-dosing period: n = 19-24/group/point, during the dosing period: n = 5-8/ group/point,) on the days shown in the Vol. 37 No. 5 ble to that in the ALF control group on the other sampling days. Absolute liver weights and liver weights relative to body weights in the RF control group were lower than those in the ALF control group at the end of the experimental period. Hepatic GSH and GSSG levels in the RF control group were lower than those in the ALF control group at the end of the experimental period. Plasma AST, ALT and GLDH activities in the RF control group were comparable to those in the ALF control group throughout the experiment period ( Table 1) .
Effects of APAP Food consumption and body weights
Absolute and relative food consumptions and body weights in the APAP-treated ALF and the APAP-treated RF groups were comparable to those in the matched control groups throughout the dosing period (Tables 2 and 3) .
Plasma glucose levels
There were no differences in the plasma glucose levels between the APAP-treated ALF or RF groups and their Body weights were measured for each rat (n = 8/group/point) on the days shown in the table. Data are shown as mean ± S.D. There were no significant differences between the matched control group and the acetaminophen-treated groups (Williams' test).
matched control groups (Fig. 1) .
Plasma and urinary endogenous metabolites
In the ALF groups, the plasma PA and LA levels were higher at 300 and 500 mg/kg (PA: 2.4-and 2.2-fold, LA: 3.7-and 4.3-fold at 300 and 500 mg/kg, respectively, as the maximum change) than those in the matched control groups from day 8 (PA) or day 21 (LA) to the end of the dosing period. In the RF groups, the plasma PA and LA levels were lower at 500 mg/kg (PA: -38%, LA: -51% as the maximum % change) than those in the matched control groups from day 21 to the end of the dosing period ( Fig. 1) . At 300 mg/kg in the RF groups, the plasma PA and LA levels were lower than those in the matched control group on some sampling days.
The plasma CRN levels in the ALF group were higher at 300 and 500 mg/kg (+14% at 300 mg/kg, +14% at 500 mg/kg as the maximum % change) than those in the matched control groups throughout the dosing period. On the other hand, in the RF group, the plasma CRN levels were lower at 500 mg/kg (-10% as the maximum % change) than those in the matched control groups throughout the dosing period (Fig. 2) . In the ALF groups, the urinary CR excretion was increased at 500 mg/kg throughout the dosing period (1.2 to 2.6-fold) when compared with that in the matched control groups. In the RF groups, the urinary CR excretion in the APAP-treated groups was comparable to that in the matched control groups throughout the dosing period (Fig. 2) .
The urinary CRN excretion in the ALF group was higher at 500 mg/kg (+19% as the maximum % change) than that in the matched control groups throughout the dosing period. At 300 mg/kg in the ALF group, the urinary CRN excretion was higher than that in the matched control group on day 99. In the RF group, the urinary CRN excretion in the APAP-treated groups was comparable to that in the matched control groups throughout the dosing period (Fig. 2) .
The urinary TAU excretion in the ALF group was similar between the control and the APAP-treated groups throughout the dosing period. In the RF groups urinary TAU excretion was lower at both dose levels (-34% at 300 mg/kg, -38% at 500 mg/kg as the maximum % change) than that in the matched control groups throughout the dosing period (Fig. 2) .
Liver weights
In the ALF groups, absolute liver weights were increased at 300 and 500 mg/kg by 14% and 15%, respectively, and relative liver weights by 15% and 20%, respectively, when compared with the matched control groups at the end of the dosing period. In the RF groups, absolute liver weights were increased at 300 and 500 mg/kg by 10% and 16%, respectively, and relative liver weights by 10% and 16%, respectively, when compared with the matched control groups at the end of the dosing period (Table 4) .
Hepatic GSH and GSSG levels
In the ALF groups, the hepatic GSH levels were increased at 300 and 500 mg/kg by 29% and 27%, respectively, at the end of the dosing period when compared with those in the matched control groups. In the RF groups, on the other hand, the hepatic GSH levels were decreased at 500 mg/kg by 15% when compared with those in the matched control group. The hepatic GSSG levels were not changed at either dose level in the ALF groups, but in the RF groups the hepatic GSSG levels were decreased at 500 mg/kg by 17% (Table 5) .
Liver function parameters
In the ALF groups, the plasma AST, ALT and GLDH activities in the APAP-treated groups were comparable to those in the matched control groups throughout the dosing period (Fig. 3) . In the RF groups, the plasma AST activity in the APAP-treated groups was comparable to that in the matched control groups throughout the dosing period. At 500 mg/kg in the RF groups, the plasma ALT activity was slightly higher (1.1-to 1.2-fold) and the plasma GLDH activity was much higher (1.6-to 3.1-fold) than those in the matched control groups from day 8 and day 21, respectively ( Fig. 3) . At 300 mg/kg in the RF groups, the plasma ALT activity was comparable to that in the matched control group throughout the dosing period, however, plasma GLDH activity was slightly higher (1.7-to 2.0-fold) than that in the matched control groups from day 49, although the change was not statistically significant (Fig. 3) .
Histopathological examination on the liver
There were no treatment-related histopathological changes in the liver in any APAP-treated group for either feeding condition.
Plasma APAP concentrations
Plasma APAP concentrations at 4 and 19 hr after dosing and AUC 4-19hr determined on day 99 increased dose-dependently both in the ALF and the RF groups. The plasma APAP concentrations in the RF groups at 4 hr after dosing of APAP (49.3 and 64.3 μg/ml at 300 and 500 mg/kg, respectively) were lower than those in the ALF groups (88.0 and 118.1 μg/ml at 300 and 500 mg/kg, respectively) when compared at the same dose levels. The AUC 4-19hr values in the RF groups were also lower than those in the ALF groups (Table 6 ). The plasma APAP concentrations in the RF groups at 19 hr after dosing of APAP were comparable to those in the ALF groups when compared at the same dose levels.
DISCUSSION
APAP-induced hepatotoxicity in humans can be broadly divided into two categories: acute toxicity after an overdose and chronic toxicity after long-term treatment at therapeutic dose levels. A one-time massive overdose of APAP induces acute hepatotoxicity both in humans and rodents, but rodents are less susceptible to the APAPinduced hepatotoxicity than humans (Tee et al., 1987) . This is because rodents have a high ability to detoxify an APAP-derived highly reactive and cytotoxic intermediate, NAPQI, by synthesis of a larger amount of glutathione Plasma CRN concentration in the RF group, C: Urinary CR excretion in the ALF group, D: Urinary CR excretion in the RF group, E: Urinary CRN excretion in the ALF group, F: Urinary CRN excretion in the RF group. G: Urinary TAU excretion in the ALF group, G: Urinary TAU excretion in the RF group. Blood samples were collected at 9:00-10:00 a.m. from each rat on the days shown in the figure (n = 5-8/group/point) under non-fasting conditions in the ALF rats or fasting conditions in the RF rats. Plasma CRN concentrations were measured with an automated analyzer using standard reagents. Urine samples were collected for 24 hr from immediately after dosing to before dosing on the next day (pre-dosing period: from 2:00 p.m. to 2:00 p.m. on the next day). Urinary CR, CRN and TAU concentrations were measured by LC/MS using internal standard. Urinary CR, CRN and TAU excretion per day was calculated by multiplying the urine volumes and the concentrations. "Pre" indicates the pre-dosing period. Data are shown as mean ± S.D. * p < 0.05, ** p < 0.01 significantly different from the matched control group (Williams' test).
than humans (Grover and Sims, 1964; Tee et al., 1987) . Even with long-term treatment with APAP, intact rodents are more resistant to APAP-induced chronic hepatotoxicity than humans and decrease their sensitivity to APAP after repeated dosing (so-called "adaptation") (O'Brien et al., 2000; Buttar et al., 1976 Buttar et al., , 1977 Strubelt et al., 1979; Poulsen and Thomsen, 1988; Shayiq et al., 1999) . This adaptation is considered to be due to the activation of an antioxidant system, which is mainly glutathione, with continuous supply of amino acids, precursors of glutathione, from the abundant diet (Buttar et al., 1977) . On the other hand, in humans, it is known that there are responders (susceptibles) and nonresponders (tolerators) in the APAP-induced chronic hepatotoxicity even though patients take APAP at therapeutic doses with a prescribed regimen (Amar and Schiff, 2007; O'Connell and Watkins, 2010; Winnike et al., 2010) . The nutritional state of the patients has been identified as one of the risk factors for APAP-induced hepatotoxicity (Amar and Schiff, 2007) and starvation appears to worsen the APAP-induced hepatotoxicity after repeated dosing of APAP even at low dose levels (Eriksson et al., 1992) .
We focused on the nutritional state which is one of the risk factors of the APAP-induced hepatotoxicity in humans and investigated APAP-induced hepatotoxicity with the restricted fed rats because the daytime-RF rats are well known to show some characteristic adaptive changes in energy metabolism, glucose synthesis and fatty acid oxidation associated with a shift of the animal's circadian rhythms (Báez-Ruiz et al., 2005; Leveille and Chakrabarty, 1968; Satoh et al., 2006; Wu et al., 2008) and to show acceleration of hepatic gluconeogenesis under restricted feeding conditions (Kobayashi et al., 2011) .
In the present study, the hepatic GSH and GSSG levels in the RF control rats were lower than those in the ALF control rats, indicating that hepatic glutathione synthesis was decreased by restricted feeding. In comparison of glutathione-related metabolites in urine and plasma between the ALF control rats and the RF control rats, the urinary CR, CRN and TAU levels and plasma CRN levels in the RF control rats were also lower than those in the ALF control rats, although the decreases in the plasma CRN and urinary TAU levels in the RF control rats were limited to the early study period. Fig. 4 shows the The liver samples were collected at the end of the dosing period. The samples (n = 8/group) were used for the measurement of hepatic GSH and GSSG levels. Data are shown as mean ± S.D. * p < 0.05, ** p < 0.01 significantly different from the matched control group (Williams' test). Vol. 37 No. 5 metabolites associated with the trans-sulfuration pathway from methionine to glutathione Schnackenberg et al., 2009) . CR and TAU are by-products of S-adenosylmethionine (SAMe) and cysteine, respectively. Therefore, the decrease in urinary CR and TAU levels in the RF control rats was considered to be related to the decrease in glutathione productivity in the liver. CRN is synthesized from CR in the muscle and released into the blood, and the decrease in urinary and plasma CRN levels in the RF control rats was considered to be due to decreased synthesis of CR. The plasma glucose levels in the control RF rats were maintained at the same levels as in the control ALF rats throughout the experiment period except for the early stage of the experimental period. This result is consistent with those previously reported (Kobayashi et al., 2011) . In a state of caloric restriction, the liver produces glucose from muscle-derived alanine via the glucose-alanine cycle (Dhahbi et al., 1999; Felig, 1973; Chakrabarty and Leveille, 1968) and, in the RF rats, the plasma glucose levels were considered to be maintained mainly by hepatic gluconeogenesis using alanine supplied by the muscles after the adaptation to the restricted feeding condition (Garber et al., 1976; Leveille and Chakrabarty, 1968) . As well as the plasma glucose levels, there were no differences in plasma PA or LA levels between the ALF and RF control rats, although these metabolites are also by-products of cysteine (Fig. 4) . PA is produced from muscle-derived alanine in the liver and is necessary to produce glucose under fasting conditions. LA is produced from PA by anaerobic metabolism of PA. The plasma samples for the measurements of acetaminophen concentration were collected at 4 and 19 hr (C 4hr and C 19hr , respectively) after dosing on day 99. The samples (n = 8/group) were used for the measurement of plasma acetaminophen concentrations. Plasma acetaminophen concentrations were measured by HPLC method after deproteination. The area under the plasma concentration-time curve ) was calculated using the trapezoidal rule. Data are shown as mean ± S.D. ## p < 0.01 significantly different between the ad libitum feeding and the restricted feeding group at the same dose (Student's t test). The absence of alteration in the plasma PA and LA levels in the RF rats was probably due to masking of glutathione depletion-related decline of PA by an accelerated gluconeogenesis-related increase in PA in the RF rats.
As the mechanism for the decrease in glutathione synthesis in the RF rats, a decrease in the intake of dietary amino acids and/or a decrease in the uptake of amino acids by the liver are considered. In the present study, there were no differences in food consumption per body weights between the ALF and RF control rats. Therefore, the decrease in the hepatic glutathione levels in the RF rats was considered not to be due to a decrease in the intake of dietary amino acids. In the RF rats, hepatic gluconeogenesis was considered to be accelerated as mentioned above and the acceleration of hepatic gluconeogenesis leads to alteration of hepatic amino acid metabolism (Dhahbi et al., 1999) . The decrease in hepatic glutathione levels in the RF rats was considered to be due to a decrease in supply of amino acids in the synthesis of glutathione because amino acids were considered to be more preferentially used for the gluconeogenesis rather than for the glutathione synthesis.
After giving APAP to the ALF rats at 300 and 500 mg/kg for 99 days, there were no changes in liver function parameters (plasma AST, ALT or GLDH activities) in the ALF rats at either dose level, indicating that the ALF rats were resistant to long-term treatment with APAP at these dose levels. In the RF rats, on the other hand, the plasma ALT activity was increased at 500 mg/kg and the plasma GLDH activity was increased both at 300 and 500 mg/kg, although there were no treatment-related histopathological findings in the liver. These results clearly indicated that repeated dosing of APAP induced mild liver injury even at 300 mg/kg in the RF rats.
As shown in Table 6 , systemic exposure to APAP was lower in the APAP-treated RF rats than that in the APAPtreated ALF rats when compared at the same dose levels and the difference in the systemic exposure was mainly due to the difference in the plasma APAP concentrations at 4 hours after dosing (plasma APAP concentrations at 4 hours after dosing on day 99: 88.0 μg/ml and 118.1 μg/ml at 300 and 500 mg/kg, respectively, in the ALF rats; 49.3 μg/ml and 64.3 μg/ml, respectively, in the RF rats). In the present study, APAP was dosed at between 2 p.m. and 3 p.m. The feeding time in the RF rats were from 10 a.m. to 2 p.m. and APAP was given immediately after finishing feeding in the RF rats. On the other hand, the ALF rats eat diet mainly during the dark period (from 7 p.m. to 7 a.m.) and eat little during the light period (from 7 a.m. to 7 p.m.). Thus, the degree of hunger in the ALF rats at the time of dosing of APAP was considered to be greater than that in the RF rats. In other words, the amount of meal in the stomach was considered to be larger in the RF rats than that in the ALF rats when APAP was dosed to these animals. Orally dosed APAP is absorbed from the small intestine (Heading et al., 1973; Clements et al., 1978) . The small-intestinal absorption of APAP is considered to be lowered by slow gastric emptying which is caused by meal in the stomach because meal in the stomach lowers gastric emptying (Burks et al., 1985; Hatanaka et al., 1994) . Low systemic exposure to APAP due to slow gastric emptying was evidenced by a clinical study reported by Heading et al. (1973) . The difference in systemic exposure to APAP between the ALF and RF rats should be also discussed from the viewpoint of metabolism because there is a diurnal variation in the activities of drug metabolizing enzymes and the variation is closely linked to a circadian rhythm (Furukawa et al., 1999) . The metabolism of APAP is also affected by the circadian rhythm and is more prominent during the dark period in rodents when the expression of clock gene Per2 is more prominent than during the day (Kakan et al., 2011) . In the present study, the RF rats were dosed APAP during the time zone (light period; between 2 p.m. and 3 p.m) when metabolism of APAP is considered to be relatively low based on the low expression of Per2 during the same time zone in the daytime restricted fed rats (Wu et al., 2010) . From this, the difference in systemic exposure to APAP between the ALF and RF rats is considered not to be due to a difference in the metabolism of APAP but to differences in the small-intestinal absorption rate of APAP between the ALF and RF rats. When the susceptibility to APAP-induced hepatotoxicity is compared between the ALF rats and RF rats with the systemic exposure ) basis, the ALF rats were resistant even at 893.3 μg·hr/ml (500 mg/kg APAP), while the hepatotoxicity could be detected in the RF rats at 373.9 μg·hr/ml (300 mg/kg APAP) which was less than the half of that in the ALF rats at 500 mg/kg. This indicates that the RF rats are much more sensitive to APAP-induced hepatotoxicity than the ALF rats.
In the RF rats, hepatic injury developed by day 8 or day 21 based on the onset of the increases in the plasma ALT and GLDH activities and consistent increases in the hepatic function parameters were observed for up to 99 days of treatment with APAP at 500 mg/kg. Further, at 300 mg/kg, the plasma hepatic function parameters increased from day 49. These results indicate that the RF rats do not adapt to APAP even during long-term treatment and that the RF rats develop APAP-induced hepatotoxicity at low doses of APAP in the late phase of the treatment period. The time course of the elevation of hepatic func-tion parameters in APAP-treated RF rats is very similar to that reported in responders to the APAP-induced chronic hepatotoxicity in a clinical trial with healthy volunteers, in which there was wide variation in the time it takes for DILI to set in and elevation of a hepatic function parameter (ALT) was observed by around day 7 of repeated doses of APAP at a dose level of 4 g/day (Watkins et al., 2006; Winnike et al., 2010) .
In the analyses of the glutathione-related metabolites after repeated dosing of APAP, the plasma CRN, PA and LA levels were increased at both dose levels and the urinary CR and CRN levels were increased at 500 mg/kg in the ALF rats. All of the plasma and urinary endogenous metabolites increased in the ALF rats after treatment with APAP are by-products synthesized in the pathway of glutathione synthesis (Fig. 4) , indicating that hepatic glutathione synthesis was enhanced for NAPQI detoxification by glutathione in the ALF rats. The increase in the hepatic GSH levels in the ALF rats after treatment with APAP supports this idea. After repeated dosing of APAP to ad libitum fed rats, the rats become resistant to the APAPinduced hepatotoxicity (O'Brien et al., 2000; Buttar et al., 1976 Buttar et al., , 1977 Strubelt et al., 1979; Poulsen and Thomsen, 1988; Shayiq et al., 1999) . This phenomenon is considered to be due to the adaptation to oxidative stress by upregulation of glutathione synthesis in the liver (O'Brien et al., 2000) . All of the changes noted in the analyses of the endogenous metabolites and hepatic glutathione in the ALF rats after repeated dosing with APAP were considered to be related to adaptation to oxidative stress caused by the reactive metabolite, NAPQI, and are consistent with findings previously reported in ad libitum fed rats after long-term treatment with APAP.
On the other hand, in the RF rats, the plasma PA, LA and CRN levels were decreased at 500 mg/kg and urinary TAU levels were decreased at both dose levels after repeated dosing with APAP. Hepatic GSH and GSSG levels were also decreased at 500 mg/kg in the APAP-treated RF rats.
PA and TAU are synthesized from cysteine, which is the precursor of glutathione, through cysteine sulphinate and hypotaurine, respectively (Fig. 4) . When APAP is given to the RF rats in which hepatic glutathione levels are lowered due to decreased supply of amino acids by restricted feeding, cysteine is considered to be used preferentially to synthesize glutathione in order to detoxify NAPQI. This potentially preferential use of cysteine for the synthesis of glutathione in the RF rats is considered to lead to a decrease in production of PA from cysteine or its metabolite, cysteine sulphinate, with a decrease in the production of LA which is an anaerobic metabolite of PA and to a decrease in the production of TAU from cysteine-sulphinate via hypotaurine. CRN is synthesized from CR which is a by-product in the synthesis of homocysteine from methionine (Fig. 4) . Methionine is synthesized from homocysteine or aspartic acid. The decrease in plasma CRN levels in the APAP-treated RF rats could be explained by alteration of both or either of the following two pathways synthesizing CR; 1) a decrease in CR synthesis due to a decrease in homocysteine synthesis caused by the preferential use of cysteine for glutathione synthesis and/or 2) a decrease in CR synthesis due to a decrease in methionine caused by preferential use of aspartic acid for gluconeogenesis. In the RF rats, the urinary CR and CRN levels, which were increased in the APAP-treated ALF rats, did not change after treatment with APAP. This phenomenon is also considered to be related to alteration of the pathways for CR and CRN synthesis, although the detailed mechanism is not known at present. The endogenous metabolite profile of the APAP-treated RF rats indicated that the RF rats do not have endogenous metabolic capacity enough to detoxify NAPQI due to lower hepatic glutathione levels caused by the preferential use of amino acids for accelerated gluconeogenesis rather than use of amino acids for glutathione synthesis with long-term restricted feeding.
Biomarkers can be broadly classified into the following three categories; predisposition biomarkers, predictive biomarkers reflecting cell defense against oxidative stress before preceding cell death and drug-related toxicity biomarkers reflecting cell death or inflammation (Antoin et al., 2009; Clayton et al., 2006; Andersson et al., 2009) . Analyzing the urinary and plasma metabolomes at various stages of drug treatment including pre-dose period may be a valuable approach to the classification of the biomarkers of these three categories and contribute to the prediction of DILI and to distinguishing susceptible patients (responders) from nonresponders to DILI. Based on a pharmaco-metabonomics approach in rats after a single dose of APAP, Clayton et al. (2006) revealed that one of the main pre-dose factors underlying the APAPinduced hepatotoxicity is the level of urinary TAU and that a higher pre-dose level of urinary TAU is associated more with resistance to the APAP-induced hepatotoxicity. This is reasonable because it is known that TAU has a hepatocyte protective effect (Waterfield et al., 1993; and prevents acetaminopheninduced hepatotoxicity (Waters et al., 2001) . In the present study, the endogenous metabolites which showed different levels between the ALF control rats and RF control rats could be potential predisposition biomarkers for the APAP-induced hepatotoxicity and the urinary TAU levels were lower in the RF control rats than those in the ALF control rats. This result is consistent with that reported by Clayton et al. (2006) and the pre-dose urinary TAU levels can be a predisposition biomarker not only for the APAPinduced acute hepatotoxicity but also for the APAPinduced chronic hepatotoxicity. In the present study, the urinary CR and CRN levels and the plasma CRN levels were also lower in the RF control rats than those in the ALF control rats. In a clinical study with ximelagatran, patients who are susceptible to ximelagatran DILI tended to have lower plasma CRN levels than nonsusceptible patients (Andersson et al., 2009) . From these observations, these plasma or urinary endogenous metabolites (TAU, CR and CRN) were considered to be potential predisposition biomarkers to predict susceptibility to DILI including the APAP-induced chronic hepatotoxicity.
In the prediction of susceptibility to the APAP-induced hepatotoxicity in humans, Winnike et al. (2010) revealed that the urinary levels of the hepatotoxic metabolites of APAP, NAPQI and APAP mercapturate and cysteine conjugates (drug-related exogenous metabolites) were not predictive by themselves and that they became predictive only when changes in the endogenous metabolite were also considered. The author also revealed that urinary CR and CRN levels, which were measured from several days before the onset of ALT elevations, were higher in nonresponders than in responders and the results indicated that the increased urinary levels of CR and CRN in nonresponders is related to increased NAP-QI detoxification by glutathione and that urinary CR and CRN levels can be predictive biomarkers to distinguish responders from nonresponders to the APAPinduced chronic hepatotoxicity . Clayton et al. (2003 Clayton et al. ( , 2004 hypothesized that the hypercreatinurea observed with hepatotoxins such as allylformate and α-naphthylisothiocyanate was due to upregulation of the biosynthesis of cysteine, which then goes on to form glutathione. A by-product of this synthesis is CR. Therefore, the elevated levels of urinary CR in human nonresponders to the APAP-induced hepatotoxicity may reflect increased glutathione synthesis to prevent toxicity. reported that a combination of urinary TAU and CR can be used to help diagnose a variety of biochemical and pathological lesions and that most compounds which deplete glutathione reduce urinary TAU and increase urinary CR levels in rats. From the results of the present study, the urinary endogenous metabolite profiles after long-term treatment with APAP in the ALF rats and RF rats are similar to those in human nonresponders and responders to APAP-induced chronic hepatotoxicity, respectively, and the differences in the profiles could be explained by differences in the tolerance of individuals to the oxidative stress caused by the APAP-derived reactive metabolite NAPQI. Glutathione-related urinary and plasma endogenous metabolites can be useful as oxidative stress-related biomarkers to predict the APAP-induced chronic hepatotoxicity both in humans and animals.
Plasma LA and PA levels are also considered to be potential biomarkers to distinguish responders from nonresponders to DILI including APAP-induced hepatotoxicity, because, in the present study, the direction of the changes in plasma LA and PA levels was different between the ALF and RF rats after treatment with APAP, although the base line levels of these two metabolites were similar between ALF and RF rats. Fannin et al. (2010) reported that serum LA levels were increased from 24 to 72 hr after treatment with a single 4 g dose, a supratherapeutic but not overtly toxic dose, of APAP in healthy adults, although the subjects did not develop liver injury, and concluded that the increase in serum LA levels was considered to be related to down-regulation of mitochondrial oxidative phosphorylation genes which was similarly noted in rats receiving a single toxic doses, 2,500 or 1,500 mg/kg, of APAP. In the present study, the LA levels were decreased in the RF rats after long-term treatment with APAP. The difference in the direction of the changes in the LA levels between the previously reported single dose study in humans and the present study may be accounted for by differences in dose levels employed in these two studies and by differences in the responses to APAP between the acute and chronic phases of APAP-induced hepatotoxicity. The usefulness of the plasma PA levels in the prediction of susceptibility to DILI is also suggested in a clinical study with ximelagatran (Andersson et al., 2009 ). In the clinical study, unbiased analysis of the plasma endogenous metabolite revealed that patients who are susceptible to ximelagatran DILI tended to have lower plasma PA levels than nonsusceptible patients and that treatment with ximelagatran tended to cause a further drop in plasma PA levels in the susceptible patients. In addition to the differences in plasma PA levels between susceptible and nonsusceptible patients, plasma endogenous metabolites related to amino acid and lipid metabolism, including L-cysteine, CRN, lecithin-cholesterol acyltransferase (LCAT), glutamic acid, alanine, ketone bodies, L-glutamine, L-phenylalanine, tyrosine and a number of mono-and triglycerides, were also identified as predisposition or putative treatment-effect biomarkers in the clinical study. From the endogenous metabolite analysis in patients who received ximelagatran, the author indicated a possibility that a limited supply of key amino acids together with a reduced supply of other key met-abolic intermediates (e.g. pyruvate) contributed to compromised protein and in particular glutathione synthesis and thereby increased sensitivity of the hepatocytes to ximelagatran. The author also suggested that the ximelagatran-sensitive patients could have been undernourished based on the metabolome profile. PA is a central metabolic intermediate in glucose, amino acid and lipid metabolism and also has cytoprotective effects against oxidative stress in biological systems (O'Donnell-Tormey et al., 1987; Desagher et al., 1997; Tsung et al., 2005; Hinoi et al., 2006; Wang and Cynader, 2001) . The results of the present study and previous observations indicate that plasma PA level is also useful not only for an oxidative stressrelated biomarker but also for a predisposition biomarker reflecting nutritional state which contributes to susceptibility to DILI.
Regarding the drug-related toxicity biomarkers reflecting cell death, the plasma GLDH activity was more sensitive than the plasma ALT activity in the present study and this observation is consistent with that reported in a previous study (O'Brien et al., 2000) . GLDH localization within the liver is regional, with higher concentrations present in the centrilobular area and therefore the detection of GLDH leakage often indicates centrilobular necrosis (Schmidt and Schmidt, 1988) , while ALT localizes mainly in the periportal hepatocytes (Hildebrand, 1983) . APAP is known to cause characteristic centrilobular necrosis (O'Brien et al., 2000) . High sensitivity of plasma GLDH activity to the APAP-induced hepatotoxicity is reasonable from the relationship between localization of the enzyme and the main target region of APAP in the liver. In the present study, plasma AST activities were did not change after treatment of APAP. The absence of a change in plasma AST activities might be explained by shorter half-life of AST (0.7-4.7 hr) compared to the half-life of ALT (72-84 hr) (Kamimoto et al., 1985; Kim, 1969) .
Finally, the features of the changes in plasma or urinary endogenous metabolites and hepatic function-related biomarkers in the RF rats after long-term treatment with APAP are similar to those reported in humans who are susceptible to the APAP-induced hepatotoxicity and indicate that the RF rats are a useful model to explain the mechanism underlying susceptibility to DILI in humans and to estimate potential hepatotoxicity of drug candidates for which rodents are supposed to be more resistant than humans from the related information including that related to potential synthesis of reactive metabolites detoxified by glutathione.
In conclusion, the RF rats are more sensitive to APAPinduced chronic hepatotoxicity than the ALF rats and did not adapt to APAP-induced hepatotoxicity even with the long-term treatment with APAP. The higher sensitivity and non-adaptable characteristics of the RF rats are considered to be related to their nutritional state; the RF rats are considered not to have endogenous metabolic capacity sufficient to detoxify the APAP-derived reactive metabolite, NAPQI, due to lower hepatic glutathione levels by the preferential use of amino acids for accelerated gluconeogenesis rather than the use of amino acids for glutathione synthesis in the long-term restricted feeding. In terms of the time course of the alteration of the hepatic function parameters and the endogenous metabolite profile, the response of the RF rats to APAP treatment is similar to that of patients who are susceptible to APAP-induced chronic hepatotoxicity. The RF rat was considered to be a useful model to estimate the contribution of the nutritional state of patients, as one of the risk factors in DILI, to APAP-induced chronic hepatotoxicity.
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